Ravi Salgia to Receptor Protein-Tyrosine Kinases
This is a "connection" page, showing publications Ravi Salgia has written about Receptor Protein-Tyrosine Kinases.
Connection Strength
7.051
-
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
Score: 0.586
-
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. BMC Cancer. 2016 08 02; 16:568.
Score: 0.526
-
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70.
Score: 0.520
-
C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype. Cancer Biol Ther. 2016; 17(1):91-103.
Score: 0.505
-
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
Score: 0.446
-
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 2014 Feb 01; 74(3):884-95.
Score: 0.438
-
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210.
Score: 0.402
-
Differential expression of RON in small and non-small cell lung cancers. Genes Chromosomes Cancer. 2012 Sep; 51(9):841-51.
Score: 0.393
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.253
-
Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets. 2005 Jun; 9(3):533-59.
Score: 0.243
-
Receptor tyrosine kinases and inhibitors in lung cancer. ScientificWorldJournal. 2004 Aug 06; 4:589-604.
Score: 0.229
-
Novel targets for therapeutic agents in small cell lung cancer. J Natl Compr Canc Netw. 2004 Mar; 2(2):165-72.
Score: 0.223
-
Role of receptor tyrosine kinases in lung cancer. Methods Mol Med. 2003; 74:113-25.
Score: 0.205
-
Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol. 2003; 22(3):147-65.
Score: 0.205
-
AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
Score: 0.196
-
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer. Clin Cancer Res. 2020 08 15; 26(16):4349-4359.
Score: 0.171
-
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treat Rev. 2017 Apr; 55:181-189.
Score: 0.138
-
RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 01 03; 10(460).
Score: 0.136
-
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
Score: 0.134
-
Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 2015 Oct; 38(5):442-7.
Score: 0.124
-
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12.
Score: 0.119
-
A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert Opin Drug Saf. 2015 Mar; 14(3):485-93.
Score: 0.119
-
AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64.
Score: 0.115
-
Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. J Biol Chem. 2014 Aug 29; 289(35):24043-58.
Score: 0.114
-
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct; 13(10):1011-9.
Score: 0.100
-
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011 Oct; 12(11):1004-12.
Score: 0.094
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.092
-
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011 May; 6(5):942-6.
Score: 0.091
-
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. J Clin Oncol. 2013 Jun 01; 31(16):e254-8.
Score: 0.026
-
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77.
Score: 0.026
-
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
Score: 0.023
-
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):2044-6.
Score: 0.022
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.022
-
Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81.
Score: 0.012